Business Standard

Vaccine had robust immune response in Phase 1 trial: Bharat Biotech

The interim findings of phase 1 clinical trial showed that the vaccine was was well tolerated in all dose groups

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

One serious adverse event was reported, which was found to be unrelated to vaccination, the findings showed

Press Trust of India
The interim findings of phase 1 clinical trial of Covid-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events.

The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent serum collected from patients who had recovered from Covid-19, according to the findings which have appeared on medRxiv, a preprint server.

A preprint is a version of a scientific manuscript posted on a public server prior to formal peer review.

One serious adverse event was reported,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Dec 16 2020 | 9:07 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com